Health Canada Approves Expanded Dosing and Pediatric Indication for FIRDAPSE in Lambert-Eaton Myasthenic Syndrome
Key Insights
Health Canada has approved Kye Pharmaceuticals (search)' supplemental new drug submission for FIRDAPSE (amifampridine), allowing some patients with Lambert-Eaton myasthenic syndrome (search) to benefit from an increased maximum daily dose of up to 100mg.
The expanded approval includes pediatric dosing guidance for patients 6 years of age and older, providing pediatric neurologists with a proven treatment option for children diagnosed with LEMS (search).
FIRDAPSE is a potassium channel (search) blocker that works by increasing acetylcholine release at the neuromuscular junction, helping improve muscle function in patients with this rare autoimmune disorder.
Kye Pharmaceuticals (search) announced that Health Canada has approved its Supplemental New Drug Submission (SNDS) for FIRDAPSE® (amifampridine), expanding dosing guidance and treatment options for patients with Lambert-Eaton myasthenic syndrome (search) (LEMS (search)). The approval allows some adult patients to benefit from a total daily dose of up to 100mg and extends the indication to include pediatric patients 6 years of age and older.
Enhanced Dosing Flexibility for Adult Patients
The expanded approval provides healthcare providers with greater flexibility in treating LEMS (search) by allowing an increased maximum daily dose of up to 100mg for some patients. This dosing guidance represents a significant advancement in treatment options for adults managing this rare autoimmune disorder characterized by muscle weakness and fatigue.
FIRDAPSE functions as a potassium channel (search) blocker that increases the release of acetylcholine, a neurotransmitter, at the neuromuscular junction. This mechanism of action helps improve muscle function in people with LEMS (search) by enhancing nerve-to-muscle communication.
Pediatric Treatment Breakthrough
The approval marks a significant milestone for pediatric care, as it includes dosing guidance for patients 6 years of age and older. This expansion offers pediatric neurologists a proven treatment option for children diagnosed with LEMS (search), addressing a critical unmet need in pediatric rare disease management.
"We are pleased to receive the approval for both the additional guidance that some patients may benefit from an increased maximum daily dose of FIRDAPSE as well as the pediatric indication starting at age six," said John McKendry, President and CEO of Kye Pharmaceuticals (search). "This expanded label highlights our continued commitment to the LEMS (search) community in Canada."
Clinical Impact and Patient Outcomes
The label update is expected to have meaningful impact on the lives of LEMS (search) patients across Canada by providing more treatment options and dosing flexibility. McKendry emphasized that the company believes this approval "will help to improve patient outcomes" for the Canadian LEMS community.
LEMS (search) is a rare autoimmune disorder that significantly impacts patients' quality of life through persistent muscle weakness and fatigue. The expanded dosing options and pediatric indication represent important advances in managing this challenging condition.
About Kye Pharmaceuticals
Kye Pharmaceuticals (search) is a growth-stage Canadian specialty pharmaceutical company focused on identifying, licensing, and commercializing novel prescription medicines for the Canadian market. The Toronto-headquartered company maintains a growing pipeline spanning multiple therapeutic areas, including cardiology, psychiatry, pediatrics, rare diseases, hematology, and neurology, with a commitment to addressing clinically significant unmet needs.